Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Cummings, Steven R., Martin, Javier San, McClung, Michael R., Siris, Ethel S., Eastell, Richard, Reid, Ian R., Delmas, Pierre, Zoog, Holly B., Austin, Matt, Wang, Andrea, Kutilek, Stepan, Adami, Silvano, Zanchetta, Jose, Libanati, Cesar, Siddhanti, Suresh, Christiansen, Claus·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0809493

Cited by (1,006)

Items 101–200 of 1,006

  1. Long-term and sequential treatment for osteoporosis
    Foessl, Ines, Dimai, Hans P., Obermayer-Pietsch, Barbara · 2023 · Nature Reviews Endocrinology
  2. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
    Socrates E. Papapoulos, Kurt Lippuner, Christian Roux, Celia J. F. Lin, David L. Kendler, Edward Michael Lewiecki, Maria Luisa Brandi, Edward J. Czerwinski, Edward Franek, Peter L. Lakatos et al. · 2015 · Osteoporosis International
  3. Biochemical markers of bone turnover – uses and limitations
    Thinn Hlaing, Juliet Elizabeth Compston · 2014 · Annals of Clinical Biochemistry International Journal of Laboratory Medicine
  4. Bone turnover markers: use in osteoporosis
    K.E. Naylor, Richard Eastell · 2012 · Nature Reviews Rheumatology
  5. The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis
    M. Neale Weitzmann · 2013 · Scientifica
  6. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
    Richard Eastell, Claus Christiansen, Andreas Grauer, Štěpán Kutílek, Cesar R. Libanati, Michael R. McClung, Ian R. Reid, Heinrich Resch, Ethel S. Siris, Daniel Uebelhart et al. · 2010 · Journal of Bone and Mineral Research
  7. Osteoporosis: Pathophysiology and therapeutic options
    Ursula Föger‐Samwald, Peter Dovjak, Ursula Azizi-Semrad, Katharina Kerschan‐Schindl, Peter Pietschmann · 2020 · EXCLI journal
  8. Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures
    Carolyn J. Crandall, Sydne Jennifer Newberry, Allison L. Diamant, Yee-Wei Lim, Walid F. Gellad, Marika J. Booth, Aneesa Motala, Paul Shekelle · 2014 · Annals of Internal Medicine
  9. The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
    Henry G. Bone, Roland D Chapurlat, Maria Luisa Brandi, Jacques P. Brown, Edward J. Czerwinski, Marc-Antoine Krieg, Dan Mellström, S. Radominski, Jean‐Yves Reginster, Heinrich Resch et al. · 2013 · The Journal of Clinical Endocrinology & Metabolism
  10. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
    Felicia Cosman, Jeri Wanzor Nieves, David W. Dempster · 2016 · Journal of Bone and Mineral Research
  11. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
    Ian R. Reid, Paul D. Miller, Jacques P. Brown, David L. Kendler, Astrid Fahrleitner‐Pammer, Ivo Valter, Katre Maasalu, Michael A. Bolognese, Grattan C. Woodson, Henry G. Bone et al. · 2010 · Journal of Bone and Mineral Research
  12. A20: from ubiquitin editing to tumour suppression
    S.G. Hymowitz, Ingrid E. Wertz · 2010 · Nature reviews. Cancer
  13. The management of cancer pain
    Judith A. Paice, Betty Ferrell · 2011 · CA A Cancer Journal for Clinicians
  14. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
    Robert B. Conley, Gemma Adib, Robert A. Adler, Kristina Åkesson, Ivy M. Alexander, Kelly C Amenta, Robert Daniel Blank, William Timothy Brox, Emily E. Carmody, Karen Chapman‐Novakofski et al. · 2019 · Journal of Bone and Mineral Research
  15. Osteoporosis
    Suzanne N. Morin, William Donald Leslie, John T. Schousboe · 2025 · JAMA
  16. The challenges of diagnosing osteoporosis and the limitations of currently available tools
    Palak U. Choksi, Karl J. Jepsen, Gregory A. Clines · 2018 · Clinical Diabetes and Endocrinology
  17. Osteoporosis and fractures in women: the burden of disease
    Mattias Lorentzon, Helena Johansson, Nicholas C. Harvey, Enwu Liu, Liesbeth Vandenput, Eugene Vincent McCloskey, John А. Kanis · 2021 · Climacteric
  18. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
    Paul D. Miller, Nicola Pannacciulli, Jacques P. Brown, Edward J. Czerwinski, Bettina S. Nedergaard, Michael A. Bolognese, Jorge Malouf, Henry G. Bone, Jean‐Yves Reginster, Andrea J. Singer et al. · 2016 · The Journal of Clinical Endocrinology & Metabolism
  19. Physiological and pathophysiological bone turnover — role of the immune system
    M. Neale Weitzmann, Ighovwerha Ofotokun · 2016 · Nature Reviews Endocrinology
  20. Central control of fever and female body temperature by RANKL/RANK
    Reiko Hanada, Andreas Leibbrandt, Toshikatsu Hanada, Shiho Kitaoka, Tomoyuki Furuyashiki, Hiroaki Fujihara, Jean Trichereau, Magdalena Paolino, Fatimunnisa Qadri, Ralph Plehm et al. · 2009 · Nature
  21. Periprosthetic Osteolysis: Mechanisms, Prevention and Treatment
    Stuart Barry Goodman, Jiří Gallo · 2019 · Journal of Clinical Medicine
  22. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Michael Gnant, Georg Pfeiler, Günther Georg Steger, Daniel Egle, Richard Greil, Florian Fitzal, Viktor Wette, Marija Balić, Ferdinand Haslbauer, Elisabeth Melbinger‐Zeinitzer et al. · 2019 · The Lancet Oncology
  23. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
    Black, Dennis M, Bauer, Douglas C, Vittinghoff, Eric, Lui, Li-Yung, Grauer, Andreas, Marin, Fernando, Khosla, Sundeep, de Papp, Anne, Mitlak, Bruce, Cauley, Jane A et al. · 2020 · The Lancet Diabetes & Endocrinology
  24. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
    Charles L. Shapiro, Catherine H. Van Poznak, Christina Lacchetti, Jeffrey J. Kirshner, Richard Eastell, Robert F. Gagel, Sean Robinson Smith, Beatrice Jara-Almonte Edwards, Elizabeth S. Frank, Gary H. Lyman et al. · 2019 · Journal of Clinical Oncology
  25. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review
    David L. Kendler, Felicia Cosman, Robert Kees Stad, Serge Ferrari · 2021 · Advances in Therapy
  26. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density
    ERIC S. ORWOLL, Christence Stubbe Teglbjærg, Bente Lomholt Langdahl, Roland D Chapurlat, Edward J. Czerwinski, David L. Kendler, Jean‐Yves Reginster, Alan Kivitz, Edward Michael Lewiecki, Paul D. Miller et al. · 2012 · The Journal of Clinical Endocrinology & Metabolism
  27. Update on Osteoporosis Screening and Management
    Anika K. Anam, Karl Leonard Insogna · 2021 · Medical Clinics of North America
  28. Osteoclast Activity and Subtypes as a Function of Physiology and Pathology—Implications for Future Treatments of Osteoporosis
    Kim Henriksen, Jens Bollerslev, Vincent E. Everts, M.A. Karsdal · 2011 · Endocrine Reviews
  29. Observations following discontinuation of long-term denosumab therapy
    Michael R. McClung, Rachel B. Wagman, Paul D. Miller, A. Wang, Edward Michael Lewiecki · 2017 · Osteoporosis International
  30. Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development
    Li, Hanxuan, Xiao, Zhousheng, Quarles, L. Darryl, Li, Wei · 2021 · Current Medicinal Chemistry
  31. Inflammation and the Osteogenic Regulation of Vascular Calcification
    Jian-Su Shao, Su‐Li Cheng, Justin S. Sadhu, Dwight A. Towler · 2010 · Hypertension
  32. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
    Sukhbinder Dhesy‐Thind, Glenn G. Fletcher, Phillip Blanchette, Mark J. Clemons, Melissa S. Dillmon, Elizabeth Frank, Sonal Gandhi, Rasna Gupta, Mihaela Mates, Beverly Moy et al. · 2017 · Journal of Clinical Oncology
  33. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials
    Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing, Sabrina Mai Nielsen, Robin Christensen, Jean‐Jacques Body, Maria Luisa Brandi, Adolfo Díez‐Pérez et al. · 2023 · BMJ
  34. Fractures in patients with CKD—diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation
    Ana Pimentel, Pablo Ureña, M. Carola Zillikens, Jordi Bover, Martine Esther Cohen-Solal · 2017 · Kidney International
  35. Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk
    Steven Boonen, Jonathan Derrick Adachi, Zulema Man, Steven Ron Cummings, Kurt Lippuner, Ove Törring, John Christopher Gallagher, Jordi Farrerons, A. Wang, Nathalie Franchimont et al. · 2011 · The Journal of Clinical Endocrinology & Metabolism
  36. Menopausal osteoporosis: screening, prevention and treatment
    Eu‐Leong Yong, Susan Jane Sinclair Logan · 2021 · Singapore Medical Journal
  37. Vertebral Fractures
    Kristine E. Ensrud, John T. Schousboe · 2011 · New England Journal of Medicine
  38. A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression
    Paul A Sutcliffe, Martin J Connock, D Shyangdan, Rachel A. Court, Ngianga‐Bakwin Kandala, Aileen Clarke · 2013 · Health Technology Assessment
  39. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (Review)
    Wei Xin Liu, Xianlong Zhang · 2014 · Molecular Medicine Reports
  40. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil
    Luiz Francisco Baccaro, Délio Marques Conde, Lúcia Costa‐Paiva, Aarão Mendes Pinto-Neto · 2015 · Clinical Interventions in Aging
  41. Osteoporosis in men
    Tatiane Vilaca, Richard Eastell, Marian Schini · 2022 · The Lancet Diabetes & Endocrinology
  42. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
    Kenneth G. Saag, Rachel B. Wagman, Piet Geusens, Jonathan Derrick Adachi, Osvaldo Daniel Messina, Ronald D. Emkey, Roland D Chapurlat, Andrea Wang, Nicola Pannacciulli, Willem Frederik Lems · 2018 · The Lancet Diabetes & Endocrinology
  43. Overview of treatment approaches to osteoporosis
    Bente Lomholt Langdahl · 2020 · British Journal of Pharmacology
  44. Antiresorptive therapies for osteoporosis: a clinical overview
    Jian Sheng Chen, Philip N. Sambrook · 2011 · Nature Reviews Endocrinology
  45. Screening to Prevent Osteoporotic Fractures
    Meera Viswanathan, Shivani Reddy, Nancy D Berkman, Katie Cullen, Jennifer Cook Middleton, Wanda Kay Nicholson, Leila C. Kahwati · 2018 · JAMA
  46. Bone Health and Osteoporosis
    Beatrice C. Lupsa, Karl Leonard Insogna · 2015 · Endocrinology and Metabolism Clinics of North America
  47. Osteoporosis – a current view of pharmacological prevention and treatment
    Julie C. Crockett, Das · 2013 · Drug Design Development and Therapy
  48. Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis
    René Rizzoli, Jean‐Yves Reginster, Steven Boonen, Gérard Bréart, Adolfo Díez‐Pérez, Dieter Felsenberg, Jean‐Marc Kaufman, John А. Kanis, Cyrus C. Cooper · 2011 · Calcified Tissue International
  49. Treating osteoporosis to prevent fractures: current concepts and future developments
    Mattias Lorentzon · 2019 · Journal of Internal Medicine
  50. Short-term and long-term effects of osteoporosis therapies
    Ian R. Reid · 2015 · Nature Reviews Endocrinology
  51. Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management
    Dennis M. Black, Bo Abrahamsen, Mary Bouxsein, Thomas A. Einhorn, Nicola Napoli · 2018 · Endocrine Reviews
  52. Pathophysiology and treatment of osteoporosis: Challenges for clinical practice in older people
    Barnsley, J., Buckland, G., Chan, P. E., Ong, A., Ramos, A. S., Baxter, M., Laskou, F., Dennison, E. M., Cooper, C., Patel, Harnish P. · 2021 · Aging Clinical and Experimental Research
  53. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review
    Erik Fink Eriksen, Adolfo Díez‐Pérez, Steven Boonen · 2013 · Bone
  54. Imminent fracture risk
    Christian Roux, Karine Briot · 2017 · Osteoporosis International
  55. Twelve years of GWAS discoveries for osteoporosis and related traits: advances, challenges and applications
    Xiaowei Zhu, Wei-Yang Bai, Hou‐Feng Zheng · 2021 · Bone Research
  56. Biologic therapies and bone loss in rheumatoid arthritis
    C. Zerbini, P. Clark, L. Méndez-Sánchez, R. M. Pereira, O. D. Messina, C. Uña, J. Adachi, W. Lems, C. Cooper, N. Lane · 2017 · Osteoporosis International
  57. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report
    Olivier Lamy, Elena González Rodríguez, Delphine Stoll, Didier B. Hans, Bérengère Aubry‐Rozier · 2016 · The Journal of Clinical Endocrinology & Metabolism
  58. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health
    David W Sturdee, Amos Pines, on behalf of the International Menopause Society Writing Group · 2011 · Climacteric
  59. Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone‐grafting procedures
    Sifat Maria, Paula Ann Witt‐Enderby · 2013 · Journal of Pineal Research
  60. State of the art in osteoporosis risk assessment and treatment
    J. Liu, Elizabeth Mary Curtis, Cyrus C. Cooper, Nicholas C. Harvey · 2019 · Journal of Endocrinological Investigation
  61. Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention
    Sougata Karmakar, Jonathan Kay, Ellen M. Gravallese · 2010 · Rheumatic Disease Clinics of North America
  62. The Relationship between Metabolic Syndrome and Osteoporosis: A Review
    Sok Kuan Wong, Kok‐Yong Chin, Farihah Haji Suhaimi, Fairus Ahmad, Soelaiman Ima-Nirwana · 2016 · Nutrients
  63. The osteoclast, bone remodelling and treatment of metabolic bone disease
    Brendan F. Boyce, Elizabeth Rosenberg, Anne E. de Papp, Le T. Duong · 2012 · European Journal of Clinical Investigation
  64. Epidemiology and management of osteoporosis in the People’s Republic of China: current perspectives
    Ling‐Qing Yuan, Xiao Lin, Dan Xiong, Yiqun Peng, Zhifeng Sheng, Xian-Ping Wu, Feng Wu, Er-Yuan Liao, Xi‐Yu Wu · 2015 · Clinical Interventions in Aging
  65. Management of severe osteoporosis
    Paul D. Miller · 2015 · Expert Opinion on Pharmacotherapy
  66. Diagnosis and treatment of osteopenia
    Gülay Karagüzel, Michael F. Holick · 2010 · Reviews in Endocrine and Metabolic Disorders
  67. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis
    Karine Briot, Bernard Cortet, Thierry Thomas, Maurice Audran, Hubert Blain, Véronique Breuil, Laure Chapuis, Roland D Chapurlat, Patrice Fardellone, Jean-Marc Féron et al. · 2012 · Joint Bone Spine
  68. Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis
    Filippo Migliorini, Nicola Maffulli, Giorgia Colarossi, Jörg Eschweiler, Markus Tingart, Marcel Betsch · 2021 · Journal of Orthopaedic Surgery and Research
  69. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
    Matthew Austin, Yuching Yang, Eric Vittinghoff, Silvano Adami, Steven Boonen, Douglas C. Bauer, Gerolamo Bianchi, Michael A. Bolognese, Claus Christiansen, Richard Eastell et al. · 2011 · Journal of Bone and Mineral Research
  70. Pituitary Diseases and Bone
    Mazziotti, Gherardo, Frara, Stefano, Giustina, Andrea · 2018 · Endocrine Reviews
  71. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
    Hatem A. Azim, Fedro Alessandro Peccatori, Sylvain Brohée, Daniel G. Branstetter, Sherene Loi, Giuseppe Viale, Martine J Piccart, William C. Dougall, Giancarlo Pruneri, Christos P. Sotiriou · 2015 · Breast Cancer Research
  72. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2
    Amel Dudakovic, Emily T. Camilleri, Fuhua Xu, Scott M. Riester, Meghan E. McGee‐Lawrence, Elizabeth W. Bradley, Christopher R. Paradise, Eric A. Lewallen, Roman Thaler, David R. Deyle et al. · 2015 · Journal of Biological Chemistry
  73. Epidemiology and pathogenesis of osteonecrosis of the jaw
    Ian R. Reid, Jillian Cornish · 2011 · Nature Reviews Rheumatology
  74. Osteoporosis, frailty and fracture: implications for case finding and therapy
    van den Bergh, Joop P., van Geel, Tineke A., Geusens, Piet P. · 2012 · Nature Reviews Rheumatology
  75. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
    Vincent Goëb, Anne‐Priscille Trouvin · 2010 · Clinical Interventions in Aging
  76. Hormone replacement therapy and the risk of breast cancer
    Steven Alexander Narod · 2011 · Nature Reviews Clinical Oncology
  77. Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range
    Ghada El‐Hajj Fuleihan, Roger Bouillon, Bart Lyman Clarke, Marlene Chakhtoura, Cyrus C. Cooper, Michael R. McClung, Ravinder Jit Singh · 2015 · Journal of Bone and Mineral Research
  78. FRAME Study: The Foundation Effect of Building Bone with 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
    Cosman, Felicia, Crittenden, Daria B, Ferrari, Serge, Khan, Aliya, Lane, Nancy E, Lippuner, Kurt, Matsumoto, Toshio, Milmont, Cassandra E, Libanati, Cesar, Grauer, Andreas · 2018 · Journal of Bone and Mineral Research
  79. RANKL/RANK control Brca1 mutation-driven mammary tumors
    Verena Sigl, Kwadwo E. Owusu-Boaitey, Purna A. Joshi, Anoop Murthy Kavirayani, Gerald Wirnsberger, Maria Novatchkova, I. Kozieradzki, Daniel Schramek, Nnamdi Edokobi, Jerome Hersl et al. · 2016 · Cell Research
  80. Management of menopause: a view towards prevention
    Roger A. Lobo, Anne Gompel · 2022 · The Lancet Diabetes & Endocrinology
  81. Osteosarcopenia: A case of geroscience
    Ben Kirk, Ahmed Al Saedi, Gustavo Duque · 2019 · Aging Medicine
  82. The RANKL-RANK Story
    Vanja Nagy, Josef Martin Penninger · 2015 · Gerontology
  83. The pathogenesis, diagnosis, investigation and management of osteoporosis
    S. K. Sandhu, Geeta Hampson · 2011 · Journal of Clinical Pathology
  84. Macrophages and skeletal health
    Megan N. Michalski, Laurie K. McCauley · 2017 · Pharmacology & Therapeutics
  85. Mechanisms of action of therapeutic antibodies for cancer
    Jason Mark Redman, Elizabeth Hill, Dalal S. Aldeghaither, Louis M. Weiner · 2015 · Molecular Immunology
  86. Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
    Toshitaka Nakamura, Toshio Matsumoto, Toshitsugu Sugimoto, Takayuki Hosoi, Takami Miki, Itsuo Gorai, Hideki Yoshikawa, Yoshiya Tanaka, Sakae Tanaka, Teruki Sone et al. · 2014 · The Journal of Clinical Endocrinology & Metabolism
  87. Osteoporosis in Rheumatic Diseases
    Giovanni Adami, Angelo Fassio, Maurizio Rossini, Cristian Caimmi, Alessandro Giollo, Giovanni Orsolini, Ombretta Viapiana, Davide Gatti · 2019 · International Journal of Molecular Sciences
  88. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
    McClung, Michael R, O'Donoghue, Michelle L, Papapoulos, Socrates E, Bone, Henry, Langdahl, Bente, Saag, Kenneth G, Reid, Ian R, Kiel, Douglas P, Cavallari, Ilaria, Bonaca, Marc P et al. · 2019 · The Lancet Diabetes & Endocrinology
  89. Denosumab: A review in postmenopausal osteoporosis
    Deeks, Emma D. · 2018 · Drugs & Aging
  90. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
    Tsutomu Takeuchi, Yoshiya Tanaka, Naoki Ishiguro, Hisashi Yamanaka, Toshiyuki Yoneda, Takeshi Ohira, Naoki Okubo, Harry K. Genant, Désirée M F M van der Heijde · 2016 · Annals of the Rheumatic Diseases
  91. Protease‐activated prodrugs: strategies, challenges, and future directions
    Marcin Poręba · 2020 · FEBS Journal
  92. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
    Sarah Davis, Emma L. Simpson, Jean Hamilton, Marrissa Martyn‐St James, Andrew Rawdin, Ruth Wong, Edward Goka, Neil J. L. Gittoes, Peter L. Selby · 2020 · Health Technology Assessment
  93. Osteoarthritis – a case for personalized health care?
    M.A. Karsdal, Claus Christiansen, Christoph H. Ladel, Kim Henriksen, Virginia B. Kraus, Anne‐Christine Bay‐Jensen · 2013 · Osteoarthritis and Cartilage
  94. Local drug delivery for enhancing fracture healing in osteoporotic bone
    Laura Kyllönen, Matteo D’Este, Mauro Alini, David Eglin · 2014 · Acta Biomaterialia
  95. Screening for Osteoporosis to Prevent Fractures
    US Preventive Services Task Force, Wanda Kay Nicholson, Michael Silverstein, John B. Wong, David P. Chelmow, Tumaini R. Coker, Esa M. Davis, Carlos Roberto Jaén, Marie A Krousel-Wood, Sei Lee et al. · 2025 · JAMA
  96. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials
    Ana Boquete‐Castro, Gerardo Gómez Moreno, José Luis Calvo‐Guirado, Antonio Aguilar‐Salvatierra, Rafael Arcesio Delgado Ruiz · 2015 · Clinical Oral Implants Research
  97. Emerging therapeutic opportunities for skeletal restoration
    Masanobu Kawai, Ulrike I. Mödder, Sundeep Khosla, Clifford james Rosen · 2011 · Nature Reviews Drug Discovery
  98. Osteoimmunology: Inflammatory osteolysis and regeneration of the alveolar bone
    Reinhard Gruber · 2019 · Journal Of Clinical Periodontology
  99. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases
    Edward Michael Lewiecki · 2013 · Therapeutic Advances in Musculoskeletal Disease
  100. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study
    Bente Lomholt Langdahl, Neil Binkley, Henry G. Bone, Nigel Leslie Gilchrist, Heinrich Resch, Jose Adolfo Rodriguez-Portales, Andrew E. Denker, Antonio Lombardi, Celine Le Bailly De Tilleghem, Carolyn A. DaSilva et al. · 2012 · Journal of Bone and Mineral Research